EA201491668A1 - VACCINES AND METHODS FOR THE TREATMENT OF LIME IN DOGS - Google Patents

VACCINES AND METHODS FOR THE TREATMENT OF LIME IN DOGS

Info

Publication number
EA201491668A1
EA201491668A1 EA201491668A EA201491668A EA201491668A1 EA 201491668 A1 EA201491668 A1 EA 201491668A1 EA 201491668 A EA201491668 A EA 201491668A EA 201491668 A EA201491668 A EA 201491668A EA 201491668 A1 EA201491668 A1 EA 201491668A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccines
dogs
methods
lime
treatment
Prior art date
Application number
EA201491668A
Other languages
Russian (ru)
Inventor
Роберт М. Лоус
Патрик Ф.М. Мейус
Джейсон Дж. Миллершип
Зак Сюй
Ричард Томас Маркони
Кристофер Эрнхарт
Original Assignee
Зоетис Ллк
Вирджиния Коммонуэлт Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зоетис Ллк, Вирджиния Коммонуэлт Юниверсити filed Critical Зоетис Ллк
Publication of EA201491668A1 publication Critical patent/EA201491668A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Согласно настоящему изобретению предложена иммуногенная композиция, содержащая антигенный фрагмент белка OspA Borrelia burgdorferi и химерный белок, содержащий антигенные фрагменты различных филотипов белка OspC Borrelia burgdorferi. Также предложены вакцины, содержащие иммуногенную композицию по изобретению, а также способы предотвращения болезни Лайма у собак и/или защиты собак от болезни Лайма с использованием вакцин.The present invention provides an immunogenic composition comprising an antigenic fragment of the OspA protein of Borrelia burgdorferi and a chimeric protein containing antigenic fragments of various phylotypes of the OspC protein of Borrelia burgdorferi. Vaccines are also provided containing the immunogenic composition of the invention, as well as methods for preventing Lyme disease in dogs and / or protecting dogs against Lyme disease using vaccines.

EA201491668A 2012-04-18 2013-04-18 VACCINES AND METHODS FOR THE TREATMENT OF LIME IN DOGS EA201491668A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261635031P 2012-04-18 2012-04-18
PCT/US2013/037063 WO2013158818A2 (en) 2012-04-18 2013-04-18 Vaccines and methods to treat lyme disease in dogs

Publications (1)

Publication Number Publication Date
EA201491668A1 true EA201491668A1 (en) 2015-08-31

Family

ID=48193279

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491668A EA201491668A1 (en) 2012-04-18 2013-04-18 VACCINES AND METHODS FOR THE TREATMENT OF LIME IN DOGS

Country Status (10)

Country Link
EP (1) EP2838555A2 (en)
JP (1) JP2015514776A (en)
CN (1) CN104379164A (en)
AR (1) AR090726A1 (en)
AU (1) AU2013249229A1 (en)
BR (1) BR112014025740A2 (en)
CA (1) CA2870179C (en)
EA (1) EA201491668A1 (en)
UY (1) UY34745A (en)
WO (1) WO2013158818A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10086057B2 (en) 2014-10-08 2018-10-02 Virginia Commonwealth University Stage specific diagnostic antigens, assay and vaccine for lyme disease
US11883476B2 (en) 2017-12-04 2024-01-30 Intervet Inc. Canine lyme disease vaccine
CN110483624B (en) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 Borrelia garinii OspA protein C-terminal peptide segment and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US6113914A (en) * 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
ATE386805T1 (en) 1998-07-31 2008-03-15 Gundersen Lutheran Medical Fou USES OF A BORRELIACID EPITOPE OF BORRELIA BURGDORFERI (OSPC) OUTSIDE MEMBRANE PROTEIN C AS A VACCINE
US20110262475A1 (en) * 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
WO2010132758A2 (en) * 2009-05-14 2010-11-18 Gomes-Solecki Maria J Ospc-based diagnostic test for lyme disease
EP3029073B1 (en) * 2010-10-20 2019-09-04 Virginia Commonwealth University Polyvalent chimeric ospc vaccinogen and diagnostic antigen

Also Published As

Publication number Publication date
WO2013158818A2 (en) 2013-10-24
JP2015514776A (en) 2015-05-21
UY34745A (en) 2013-11-29
AR090726A1 (en) 2014-12-03
EP2838555A2 (en) 2015-02-25
BR112014025740A2 (en) 2017-07-04
CA2870179A1 (en) 2013-10-24
AU2013249229A1 (en) 2014-10-23
CN104379164A (en) 2015-02-25
CA2870179C (en) 2018-09-04
WO2013158818A3 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CY1123739T1 (en) ANTI-CD38 ANTIBODIES
CY1120772T1 (en) Mutated OspA FRAGMENTS AND RELATED METHODS AND USES
EA201790294A1 (en) FLAGELLIN BASED MEANS AND APPLICATIONS INCLUDING EFFECTIVE VACCINATION
MX2012013261A (en) Chimeric ospa genes, proteins, and methods of use thereof.
EA201391457A1 (en) PROTEINS CONNECTING WITH BCMA (CD269 / TNFRSF17)
EA201401204A1 (en) ANTIBODIES TO IL-23P19
EA201001491A1 (en) REPLICATION-DEFECT VACCINES AND VACCINE VECTORS AGAINST FLAVIVIRUSS
EA201792465A1 (en) CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
EA201401077A1 (en) BISPECIFIC ANTIBODIES TO HUMAN TWEAK AND HUMAN IL17 AND THEIR APPLICATION
EA201890548A1 (en) ANTIBODIES TO IL-23
EA201391240A1 (en) SLIP PROTEINS AND COMBINED VACCINES CONTAINING PROTEIN E AND PILIN A HAEMOPHILUS INFLUENZA
EA201390772A1 (en) NEW SALTS AND POLYMORPHIC FORMS OF AFATINIBA
UA118332C2 (en) Cs27l antigen binding proteins
EA201690159A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
EA201792407A3 (en) COMPOSITIONS CONTAINING BUFFER, COMPOSITIONS OF VACCINES THAT CONTAIN COMPOSITIONS CONTAINING BUFFER AND WAYS OF THEIR APPLICATION
EA201301107A1 (en) MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI)
CY1121734T1 (en) MUTANT OspA FRAGMENTS AND METHODS AND USES THEREOF
AR093620A1 (en) BMP-6 ANTIBODIES
BR112015020079A8 (en) COMPOSITIONS FOR ORAL CARE
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201491668A1 (en) VACCINES AND METHODS FOR THE TREATMENT OF LIME IN DOGS
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
EA201290319A1 (en) APPLICATION OF L3 AND / OR L5 SOURCE AS A VACCINE OR DIAGNOSTIC MEANS FOR PARASITIC DISEASE
BR112015020053B8 (en) COMPOSITIONS FOR ORAL CARE
EA201200723A1 (en) ANTIGENS ACTINOBACILLUS SUIS